Smart implants with intrinsic biosynthetic gene expression mechanisms and compound-selective feedback control can be considered molecular factories which may provide new treatment opportunities in future gene- and cell-based therapies.
In this project, an optogenetic method to stimulate hormone production by β-cell-mimetic designer cells will be implemented in a bio-compatible implant that will be gradually equipped with complex functionalities ranging from feedback control over semi-autarkic power supply to telemetry with remote artificial intelligence systems for continuous implant control and treatment adjustment.